Vaxcyte
PCVX
323 hedge funds and large institutions have $11.5B invested in Vaxcyte in 2024 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 139 increasing their positions, 90 reducing their positions, and 62 closing their positions.
87% more call options, than puts
Call options by funds: $48.1M | Put options by funds: $25.7M
54% more repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 90
0.88% more ownership
Funds ownership: 112.07% → 112.96% (+0.88%)
0% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 62
2% less funds holding
Funds holding: 328 → 323 (-5)
26% less capital invested
Capital invested by funds: $15.6B → $11.5B (-$4.07B)
48% less funds holding in top 10
Funds holding in top 10: 23 → 12 (-11)
Top Buyers
Top Sellers
PCVX Hedge Fund Activity: Q4 2024 in Review
323 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q4 2024, worth a combined $11.5B — down 26% from $15.6B a quarter earlier.
Fund positioning in PCVX was balanced in Q4 2024: 62 funds opened new positions, 62 closed out, 139 added to existing stakes and 90 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $217M. The largest seller was Fidelity Investments, cutting an estimated $269M.
- 323 institutional investors held Vaxcyte (PCVX) as of Q4 2024, down from 328 in Q3 2024.
- Funds reported $11.5B of Vaxcyte stock for Q4 2024, down 26% quarter-over-quarter.
- 62 funds opened new Vaxcyte positions in Q4 2024 and 62 closed out, a net change of 0 holders.
- The largest Vaxcyte buyer in Q4 2024 was Goldman Sachs, an estimated $217M added.
- The largest Vaxcyte seller in Q4 2024 was Fidelity Investments, an estimated $269M sold.
Based on aggregated 13F filings for Q4 2024.